{"downloaded": true, "htmlmade": false, "full": {"id": "32871874", "source": "MED", "pmid": "32871874", "pmcid": "PMC7458241", "fullTextIdList": {"fullTextId": "PMC7458241"}, "doi": "10.1097/md.0000000000021576", "title": "Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.", "authorString": "Watanabe H, Hattori T, Kume A, Misu K, Ito T, Koike Y, Johnson TA, Kamitsuji S, Kamatani N, Sobue G.", "authorList": {"author": [{"fullName": "Watanabe H", "firstName": "Hirohisa", "lastName": "Watanabe", "initials": "H", "authorId": {"@type": "ORCID", "#text": "0000-0001-8553-8536"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya."}, {"affiliation": "Fujita Health University School of Medicine, Department of Neurology, Toyoake."}]}}, {"fullName": "Hattori T", "firstName": "Tatsuya", "lastName": "Hattori", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Honmachi Clinic, Naka-ku."}}}, {"fullName": "Kume A", "firstName": "Akito", "lastName": "Kume", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "KUME Clinic, Mizuho-ku, Nagoya."}}}, {"fullName": "Misu K", "firstName": "Kenichiro", "lastName": "Misu", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "MISU Clinic, Miyoshi."}}}, {"fullName": "Ito T", "firstName": "Takashi", "lastName": "Ito", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Saishukan Hospital, Kitanagoya, Aichi."}}}, {"fullName": "Koike Y", "firstName": "Yu", "lastName": "Koike", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "OASIS Clinic, Ushiku, Ibaraki."}}}, {"fullName": "Johnson TA", "firstName": "Todd A", "lastName": "Johnson", "initials": "TA", "authorId": {"@type": "ORCID", "#text": "0000-0003-3377-6692"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "StaGen Co., Ltd., Taito-ku, Tokyo, Japan."}}}, {"fullName": "Kamitsuji S", "firstName": "Shigeo", "lastName": "Kamitsuji", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "StaGen Co., Ltd., Taito-ku, Tokyo, Japan."}}}, {"fullName": "Kamatani N", "firstName": "Naoyuki", "lastName": "Kamatani", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "StaGen Co., Ltd., Taito-ku, Tokyo, Japan."}}}, {"fullName": "Sobue G", "firstName": "Gen", "lastName": "Sobue", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-8553-8536"}, {"@type": "ORCID", "#text": "0000-0003-3377-6692"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "35", "volume": "99", "journalIssueId": "3003920", "dateOfPublication": "2020 Aug", "monthOfPublication": "8", "yearOfPublication": "2020", "printPublicationDate": "2020-08-01", "journal": {"title": "Medicine", "ISOAbbreviation": "Medicine (Baltimore)", "medlineAbbreviation": "Medicine (Baltimore)", "NLMid": "2985248R", "ISSN": "0304-5412", "ESSN": "1536-5964"}}, "pubYear": "2020", "pageInfo": "e21576", "abstractText": "<h4>Background</h4>Cellular energetics play an important role in Parkinsons disease etiology, but no treatments directly address this deficiency. Our past research showed that treatment with febuxostat and inosine increased blood hypoxanthine and ATP in healthy adults, and a preliminary trial in 3 Parkinson's disease patients suggested some symptomatic improvements with no adverse effects.<h4>Methods</h4>To examine the efficacy on symptoms and safety in a larger group of Parkinsons disease patients, we conducted a single-arm, open-label trial at 5 Japanese neurology clinics and enrolled thirty patients (nmales\u200a=\u200a11; nfemales\u200a=\u200a19); 26 patients completed the study (nmales\u200a=\u200a10; nfemales\u200a=\u200a16). Each patient was administered febuxostat 20\u200amg and inosine 500\u200amg twice-per-day (after breakfast and dinner) for 8 weeks. The primary endpoint was the difference of MDS-UPDRS Part III score immediately before and after 57 days of treatment.<h4>Results</h4>Serum hypoxanthine concentrations were raised significantly after treatment (Pre\u200a=\u200a11.4\u200a\u03bcM; Post\u200a=\u200a38.1\u200a\u03bcM; P\u200a<\u200a.0001). MDS-UPDRS Part III score was significantly lower after treatment (Pre\u200a=\u200a28.1\u200a\u00b1\u200a9.3; Post\u200a=\u200a24.7\u200a\u00b1\u200a10.8; mean\u200a\u00b1\u200aSD; P\u200a=\u200a.0146). Sixteen adverse events occurred in 13/29 (44.8%) patients, including 1 serious adverse event (fracture of the second lumbar vertebra) that was considered not related to the treatment.<h4>Conclusions</h4>The results of this study suggest that co-administration of febuxostat and inosine is relatively safe and effective for improving symptoms of Parkinsons disease patients. Further controlled trials need to be performed to confirm the symptomatic improvement and to examine the disease-modifying effect in long-term trials.", "affiliation": "Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial", "research-article", "Multicenter Study", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Nervous System Diseases", "meshQualifierList": {"meshQualifier": {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Parkinson Disease", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Hypoxanthine", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Xanthine Dehydrogenase", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Inosine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Adenosine Triphosphate", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Gout Suppressants", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Drug Therapy, Combination"}, {"majorTopic_YN": "N", "descriptorName": "Administration, Oral"}, {"majorTopic_YN": "N", "descriptorName": "Case-Control Studies"}, {"majorTopic_YN": "N", "descriptorName": "Safety"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Japan", "meshQualifierList": {"meshQualifier": {"abbreviation": "EP", "qualifierName": "epidemiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Febuxostat", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}]}, "chemicalList": {"chemical": [{"name": "Gout Suppressants", "registryNumber": "0"}, {"name": "Xanthine Dehydrogenase", "registryNumber": "EC 1.17.1.4"}, {"name": "Adenosine Triphosphate", "registryNumber": "8L70Q75FXE"}, {"name": "Hypoxanthine", "registryNumber": "2TN51YD919"}, {"name": "Inosine", "registryNumber": "5A614L51CT"}, {"name": "febuxostat", "registryNumber": "101V0R1N2E"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1097/MD.0000000000021576"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7458241"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7458241?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2020-09-14", "dateOfCreation": "2020-09-03", "firstIndexDate": "2020-09-02", "fullTextReceivedDate": "2020-09-13", "dateOfRevision": "2021-01-12", "firstPublicationDate": "2020-08-01"}, "htmllinks": "https://europepmc.org/articles/PMC7458241", "abstract": "<h4>Background</h4>Cellular energetics play an important role in Parkinsons disease etiology, but no treatments directly address this deficiency. Our past research showed that treatment with febuxostat and inosine increased blood hypoxanthine and ATP in healthy adults, and a preliminary trial in 3 Parkinson's disease patients suggested some symptomatic improvements with no adverse effects.<h4>Methods</h4>To examine the efficacy on symptoms and safety in a larger group of Parkinsons disease patients, we conducted a single-arm, open-label trial at 5 Japanese neurology clinics and enrolled thirty patients (nmales\u200a=\u200a11; nfemales\u200a=\u200a19); 26 patients completed the study (nmales\u200a=\u200a10; nfemales\u200a=\u200a16). Each patient was administered febuxostat 20\u200amg and inosine 500\u200amg twice-per-day (after breakfast and dinner) for 8 weeks. The primary endpoint was the difference of MDS-UPDRS Part III score immediately before and after 57 days of treatment.<h4>Results</h4>Serum hypoxanthine concentrations were raised significantly after treatment (Pre\u200a=\u200a11.4\u200a\u03bcM; Post\u200a=\u200a38.1\u200a\u03bcM; P\u200a<\u200a.0001). MDS-UPDRS Part III score was significantly lower after treatment (Pre\u200a=\u200a28.1\u200a\u00b1\u200a9.3; Post\u200a=\u200a24.7\u200a\u00b1\u200a10.8; mean\u200a\u00b1\u200aSD; P\u200a=\u200a.0146). Sixteen adverse events occurred in 13/29 (44.8%) patients, including 1 serious adverse event (fracture of the second lumbar vertebra) that was considered not related to the treatment.<h4>Conclusions</h4>The results of this study suggest that co-administration of febuxostat and inosine is relatively safe and effective for improving symptoms of Parkinsons disease patients. Further controlled trials need to be performed to confirm the symptomatic improvement and to examine the disease-modifying effect in long-term trials.", "pdflinks": "https://europepmc.org/articles/PMC7458241?pdf=render", "journaltitle": "Medicine", "authorinfo": ["Watanabe H", "Hattori T", "Kume A", "Misu K", "Ito T", "Koike Y", "Johnson TA", "Kamitsuji S", "Kamatani N", "Sobue G"], "title": "Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine."}